AI Startup Nome Builds Custom Drug Development Roadmaps for Ultra-Rare Disease Patients

A startup called Nome is positioning itself as a contract research organization dedicated to ultra-rare disease patient groups — communities too small to attract sustained attention from major pharmaceutical companies — using an AI platform to help families map a credible path from diagnosis to clinical development.

The company was founded by Stevie Ringel, who developed the idea after his own experience navigating the rare disease landscape as a teenager, when both he and his sister were diagnosed with a type of retinal dystrophy caused by a mutation of the KIZ gene. The condition affects fewer than 200 patients globally and has no FDA-approved treatment options.

Ringel went on to launch the Kizuna Foundation and raised money toward developing an individualized treatment, but he found the process taxing and uncertain. He designed Nome to be, in his words, the resource his own foundation had lacked — a service that guides small patient groups after funds are raised, but before significant capital is deployed.

"As a patient, it would have made a world of difference to me to hear, you know, actually there's something we can do. It's gonna be long and hard and potentially expensive, but there's a pathway here that's credible, here's what it is, and here's how you can take action — versus, sorry, go learn Braille," Ringel said.

Nome describes its offering as a "white glove service" for underserved patient populations. After a patient receives a genetic test identifying a disorder, they can upload the results into Nome's system, which uses a proprietary AI platform to analyze the data and begin generating a development strategy. The company currently oversees more than 10 genetic medicine programs.

"We act with patient-level urgency and are highly focused on providing a roadmap forward for an underserved part of the market," Ringel said.

One of Nome's recent clients is The DAND Alliance, a parent-led advocacy group focused on DEAF1-Associated Neurodevelopmental Disorder, or DAND — an ultra-rare group of genetic conditions characterized by developmental delays, intellectual disability, and autism. Only about 200 patients have been diagnosed with the disease worldwide.

The alliance was founded by Jacalyn Lee and four other mothers after Lee's youngest daughter, Isla, was diagnosed with DAND at age three. Lee, who works as a communications strategist, said the group had raised money toward a treatment but struggled to determine how to deploy it effectively.

"We were trying to figure out where should we spend money, knowing that we only have so much. But really we wanted this final document that was board-ready, that we could use to fundraise against, that we could use to operationalize against," Lee said.

Nome responded with a 53-page report outlining next steps — covering everything from animal studies to trial design — and identifying researchers and vendors the alliance should consider engaging.

"They helped us figure out what the gaps are, what work streams we need to prioritize, and even potential researchers or vendors that we need to think about engaging with," Lee said.

Lee said the speed and cost of Nome's work surprised her, noting that the alliance was early-stage and operating with limited funding.

"I think he got it in terms of the speed in which we wanted to move and how urgent this was for us, the fact that we were so new, we didn't have a lot of funding," she said.

Nome's broader ambition extends beyond producing reports. The company's longer-term goal is to reduce the cost of individualized therapies and make them more attainable for small patient populations — and potentially, one day, to establish a path for insurance coverage of such treatments.

"People come to us one family at a time, or as a collection of families," Ringel said, underscoring a model built around the unit economics of patient advocacy rather than the scale economics of traditional drug development.

With more than 10 active genetic medicine programs now in its portfolio, Nome is signaling that demand for this kind of structured, AI-assisted guidance exists — and that it is arriving from communities that have historically had nowhere else to turn.

Disclaimer